Ignite Creation Date:
2025-12-24 @ 3:45 PM
Ignite Modification Date:
2026-05-05 @ 5:03 AM
Study NCT ID:
NCT05903092
Status:
RECRUITING
Last Update Posted:
2025-05-04
First Post:
2023-06-05
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
Sponsor:
Hirva Mamdani
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
HCRN LUN21-530
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None